SCHEDULE: Valneva SE: Bpifrance Group Adjusts Stake in Reserved Offering

Bpifrance Participations, EPIC Bpifrance, Bpifrance S.A., Caisse des Depots et Consignations, and CDC Croissance S.A. have filed an amendment to their Schedule 13D, detailing changes in their beneficial ownership of Valneva SE ordinary shares following a reserved offering and subsequent trading activities.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of Valneva SE ordinary shares by several French entities collectively referred to as the Reporting Persons.
• The Reporting Persons include Bpifrance Participations S.A., EPIC Bpifrance, Bpifrance S.A., Caisse des Depots et Consignations (CDC), and CDC Croissance S.A.
• Valneva SE completed an EUR 84 million reserved offering on May 5, 2026, issuing 15,893,817 new ordinary shares with attached warrants.
• The Reporting Persons did not participate in this reserved offering, which resulted in a dilution of their holdings.
• Bpifrance Participations sold 356,003 ordinary shares in March 2026.
• CDC Croissance S.A. acquired 130,000 ordinary shares and sold 289,645 ordinary shares between March 9 and March 30, 2026.
• As of May 5, 2026, the Reporting Persons' beneficial ownership is calculated based on voting rights, with Bpifrance Participations holding 7,158,835 shares (14,317,670 voting rights, 7.0% of voting rights) and CDC Croissance S.A. holding 4,755,872 shares (4,755,872 voting rights, 2.3% of voting rights).
• The total voting rights held by the group, considering indirect ownership and double voting rights, are significant, with CDC holding 19,074,653 voting rights (9.3% of voting rights) and Bpifrance holding 14,317,670 voting rights (7.0% of voting rights).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting standard adjustments by major shareholders to a dilutive capital raise event rather than a significant positive or negative development for the company itself.

Positives

• The reserved offering successfully raised EUR 84 million for Valneva SE, indicating investor confidence in the company's prospects.
• The Reporting Persons continue to hold substantial stakes in Valneva SE, demonstrating ongoing strategic interest.
• Bpifrance Participations and CDC Croissance S.A. have actively managed their positions through open market transactions, potentially optimizing their investment.
• The double voting rights associated with certain shares held by Bpifrance and CDC provide them with significant influence over corporate decisions.

Negatives

• The reserved offering resulted in a dilution of the Reporting Persons' holdings, reducing their percentage ownership.
• Bpifrance Participations experienced a net sale of shares in March 2026.
• CDC Croissance S.A. also experienced a net sale of shares in March 2026, despite some acquisitions.

Risks

• The dilution from the reserved offering could impact the Reporting Persons' influence and future returns.
• Future open market sales by the Reporting Persons could put downward pressure on Valneva SE's share price.
• The extinguishment of double voting rights upon sale of shares by Bpifrance Participations means their voting power is directly tied to their shareholding.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Valneva SE. However, the Reporting Persons reserve the right to change their investment intent, acquire additional securities, or dispose of their holdings.

Management Comments

• The Reporting Persons undertake to provide full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D, upon request.
• The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law.
• The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.
• As part of the ongoing evaluation of investment and investment alternatives, the Reporting Persons may consider matters related to Items 4(a)-(j) of the Instructions to Schedule 13D and, subject to applicable law, may formulate a plan with respect thereto, and, from time to time, may hold discussions with or make formal proposals to management or the board of directors of the Issuer or other third parties regarding such matters.

Industry Context

StockSavvy.ai notes that this filing reflects typical adjustments by significant institutional investors following a capital raise event, particularly in the biotechnology or pharmaceutical sector where such events are common for funding R&D and clinical trials. The dilution and subsequent trading activity are standard responses to such corporate actions.

Stakeholder Impact

• Shareholders: Dilution of ownership percentage due to the reserved offering for non-participating shareholders. Potential impact on share price from ongoing trading activities of Bpifrance and CDC Croissance.
• Company Management/Board: The significant voting power held by the Reporting Persons may influence future corporate decisions and strategic direction.
• Creditors: No direct impact mentioned, but successful capital raises can strengthen a company's financial position.

Next Steps

• The Reporting Persons may continue to evaluate their investment and may acquire or dispose of additional securities.
• The Reporting Persons may engage in discussions with management or the board of directors regarding strategic matters.
• The reserved offering is expected to close on May 5, 2026.

Key Dates

Recommendation

The filing details adjustments by significant institutional investors following a dilutive capital raise. While the dilution is a negative for existing shareholders, the capital raised is positive for the company's operations. The ongoing strategic interest and substantial voting power of the Bpifrance group and CDC suggest a continued commitment, warranting a 'hold' recommendation pending further operational or strategic developments from Valneva SE.

Keywords

Valneva SE, Schedule 13D, Bpifrance, Caisse des Depots et Consignations, Reserved Offering, Share Dilution, Beneficial Ownership, Voting Rights, Securities Exchange Act